SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Causes and consequences of aberrant mRNA translation in cancer

This project aims to investigate aberrant mRNA translation in cancer due to amino acid shortages, linking it to tumor progression and developing novel therapeutic strategies.

Subsidie
€ 2.500.000
2024

Projectdetails

Introduction

Shortages in amino acids are weapons in the warfare between tumor cells and tumor-infiltrating lymphocytes. Tumor cells enhance or inhibit the production of key amino acid metabolites to stimulate oncogenesis and suppress anti-tumor activity. A key player in this battle is tryptophan.

Mechanism of Action

Activated T cells secrete interferon-γ, which upregulates the IDO1 enzyme to catabolize tryptophan to kynurenine in target tumor cells. While kynurenine suppresses T-cell function, its production limits tryptophan availability in tumor cells.

Consequences of Tryptophan Shortage

Importantly, as tumor cells almost invariably deregulate mRNA translation to promote proliferation and metastasis, the consequences of tryptophan shortage are major. It provokes aberrant mRNA translation at tryptophan codons, resulting in:

  1. Ribosomal frameshifting
  2. Tryptophan to phenylalanine (W>F) codon reassignments (substitutants)

This aberrant mRNA translation alters protein function and enriches the landscape of neoepitopes at the surface of tumor cells. Based on these observations, I hypothesize that the detection of aberrant proteins in cancer specimens can reveal additional key processes of cancer progression beyond tryptophan that can be utilized for cancer therapy.

Work Packages

To explore this exciting new idea, I designed three work packages (WPs):

  • WP1: Expand the landscape of aberrant mRNA translation in cancer and link them to cancerous events. Preliminary results pinpoint arginine, histidine, and leucine.

  • WP2: Generate reporter assays, set up functional genetic screens, and identify, validate, and explore key regulators of aberrant mRNA translation.

  • WP3: Study the functional consequences of aberrant mRNA translation and introduce novel therapeutic concepts.

Conclusion

Altogether, this proposal will employ our recent discoveries of aberrant mRNA translation during periods of amino acid shortages to explore novel interplays between cancers and their suppressive microenvironment, and utilize this new knowledge for cancer therapy.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 2.500.000

Tijdlijn

Startdatum1-9-2024
Einddatum31-8-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUISpenvoerder

Land(en)

Netherlands

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Targeting the Metabolic Dependencies of Metastatic Tumor Cells

This project aims to identify and target unique amino acid dependencies in metastatic melanoma cells to develop novel therapies that prevent metastasis and improve cancer treatment outcomes.

ERC Starting...€ 1.493.750
2024
Details

Unraveling Ribosome Heterogeneity: Implications for Metastasis and Beyond

This project aims to map ribosomal heterogeneity in metastatic cancers to uncover how specialized ribosomes influence oncogenic translation and metastasis, potentially identifying new cancer biomarkers and therapies.

ERC Starting...€ 1.500.000
2025
Details

Species-specific aspects in eukaryotic mRNA translation modulation and their implications in diseases

This project aims to investigate species-specific mRNA translation mechanisms in mammals and kinetoplastid parasites to inform new treatments for diseases like cancer and infections.

ERC Consolid...€ 1.999.539
2023
Details

Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy

This project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients.

ERC Starting...€ 1.499.250
2023
Details

An integrative genetic approach for the exploration of melanoma immunological interactions

This project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses.

ERC Advanced...€ 2.500.000
2023
Details
ERC Starting...

Targeting the Metabolic Dependencies of Metastatic Tumor Cells

This project aims to identify and target unique amino acid dependencies in metastatic melanoma cells to develop novel therapies that prevent metastasis and improve cancer treatment outcomes.

ERC Starting Grant
€ 1.493.750
2024
Details
ERC Starting...

Unraveling Ribosome Heterogeneity: Implications for Metastasis and Beyond

This project aims to map ribosomal heterogeneity in metastatic cancers to uncover how specialized ribosomes influence oncogenic translation and metastasis, potentially identifying new cancer biomarkers and therapies.

ERC Starting Grant
€ 1.500.000
2025
Details
ERC Consolid...

Species-specific aspects in eukaryotic mRNA translation modulation and their implications in diseases

This project aims to investigate species-specific mRNA translation mechanisms in mammals and kinetoplastid parasites to inform new treatments for diseases like cancer and infections.

ERC Consolidator Grant
€ 1.999.539
2023
Details
ERC Starting...

Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy

This project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients.

ERC Starting Grant
€ 1.499.250
2023
Details
ERC Advanced...

An integrative genetic approach for the exploration of melanoma immunological interactions

This project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses.

ERC Advanced Grant
€ 2.500.000
2023
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering

The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.

EIC Accelerator€ 2.434.790
2025
Details
EIC Accelerator

Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering

The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.

EIC Accelerator
€ 2.434.790
2025
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.